Alphatec Holdings (ATEC) Stock Sinks As Margin Gains Fail To Convince

Alphatec Holdings just gave shareholders a jolt. The stock closed at US$9.57, down about 7.5% on the day, even though the headline from Q2 was clear. Revenue reached about US$214 million and adjusted earnings before interest, tax, depreciation and amortisation climbed to about US$36 million.

Short term traders focused on the red on the screen. Longer term investors will likely be more interested in what this quarter says about Alphatec Holdings’ push toward higher margins, sustained double digit top line growth and the wider multi year earnings and valuation story.

Is Alphatec Holdings trading at a steep discount to its stated fair value, or does the low price simply reflect ongoing losses and volatility? Compare the current share price against our detailed valuation analysis for Alphatec Holdings.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$213.5 million vs. US$185.5 million (up about 15%).
• Net Income/Loss, Q2 2026 vs. Q2 2025: loss of US$25.8 million vs. loss of US$41.1 million (loss narrowed).
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.16 per share vs. loss of US$0.27 per share (loss per share narrowed).
• Adjusted EBITDA, Q2 2026 vs. Q2 2025: US$36 million vs. about US$23.5 million (up about 53%) with a 17% margin in Q2 2026.

Prefer clean visuals over scrolling through another wall of numbers and jargon filled filings? See Alphatec Holdings’ full financial picture with a clear view of its revenue and profitability trends in our company report for Alphatec Holdings.

Alphatec bullish thesis meets real operating tests

Fans of Alphatec Holdings argue that surgeon adoption and an integrated spine ecosystem will turn high case growth into durable margins and cash. Q2 gives that claim some real backing. Surgical revenue of US$196 million with case volumes up about 20% and surgeon adds up about 24% shows the adoption engine working. Gross margin at 72.5% and adjusted EBITDA of US$36 million at a 17% margin, up meaningfully year on year, point to operating leverage rather than just buying growth. Positive free cash flow alongside about US$204 million of liquidity and lower interest expense from the refinancing supports the idea that the model can fund its own instrument and R&D spend. Management also reaffirmed revenue guidance and raised the full year EBITDA target, which aligns with the narrative that scale is starting to stick.

Bear case on Alphatec execution not closed

The skeptics focus on two things: execution risk around growth assets like EOS and Valence, and the possibility that heavy investment and past losses resurface if growth stumbles. Q2 answers some of that, but not all. EOS revenue of US$17 million and comments about “bumpy” installation cadence and only roughly 15% to 20% EOS Insight penetration show that data and imaging are still in early innings, with timing risk intact. Revenue per case is still down about 2.7% year on year, driven largely by weaker biologics attachment, so case growth is doing more work than pricing. Legal investigations that began after Q1 remain an overhang, and the stock fell about 7.5% on the print, which suggests investors are not yet treating improved EBITDA and cash flow as a permanent fix.

Compare how Alphatec Holdings’ margin progress and cash generation stack up against the recent 7.5% share price drop, then see whether analysts think the stock is mispriced with the consensus price target analysis for Alphatec Holdings.

Take Control Of Your Next Move

If the Q2 mix of margin progress, ongoing losses and that 7.5% drop has put Alphatec Holdings on your radar, register free with Simply Wall St and add it to your Watchlist to track the share price against fair value and spot an entry that fits your plan. Once you are invested, manage your positions through the Portfolio Command Center so you only see focused alerts on earnings, valuation shifts and major company developments rather than day to day noise. For a longer term view, tap into what other investors are watching and debating through the Community to pressure test your thesis from different angles. That way you can surface hidden catalysts or emerging risks early and stay a step ahead of the market.

Seeking Alternatives Before Momentum Flies Past

Fresh themes can move from quiet to breakout fast. Use these under the radar lists while it matters and before momentum gets fully caught by the crowd. Get in early.

• Spot robust balance sheets before the momentum rush and scan the curated list of solid balance sheet and fundamentals stocks (48 results) to find businesses built to handle shocks while others are still reacting.
• Ride powerful income streams as yields keep investors watching and sift through our hand picked 8 dividend fortresses to see which payers still look ready to hold up.
• Stay ahead of the next surge in power demand and comb through carefully filtered 36 power grid technology and infrastructure stocks to find companies tied to grid upgrades while interest is still building.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com